China biotech’s ‘coming out party’ masks long road ahead

LONDON/SHANGHAI (Reuters) – Investors are betting on China’s potential to feed the global pharmaceutical pipeline, putting a multi-billion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.
( read original story …)

Related Post